4.8 Article

Life-Threatening Influenza, Hemophagocytic Lymphohistiocytosis and Probable Vaccine-Strain Varicella in a Novel Case of Homozygous STAT2 Deficiency

期刊

FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.624415

关键词

type I interferon; type I and type III interferon signaling; JAK-STAT signaling pathway; viral disease; hyperinflammation; interferon stimulated gene; inborn errors of antiviral immunity; varicella zoster virus

资金

  1. Wellcome Trust [207556/Z/17/Z, 211153/Z/18/Z]
  2. British Medical Association
  3. Wellcome Trust [211153/Z/18/Z, 207556/Z/17/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

This study identified a novel genetic cause of homozygous STAT2 deficiency with unique clinical features, including HLH, severe influenza, and vaccine-strain varicella. Genetic investigation revealed a novel nonsense STAT2 variant that led to a lack of STAT2 protein expression and impaired IFN-I signaling. The occurrence of life-threatening influenza and vaccine-strain varicella in association with STAT2 deficiency highlights the critical role of IFN-I/III immunity in viral infections and vaccine responses.
STAT2 is a transcription factor that plays an essential role in antiviral immunity by mediating the activity of type I and III interferons (IFN-I and IFN-III). It also has a recently established function in the negative regulation of IFN-I signaling. Homozygous STAT2 deficiency is an ultra-rare inborn error of immunity which provides unique insight into the pathologic consequence of STAT2 dysfunction. We report here a novel genetic cause of homozygous STAT2 deficiency with several notable clinical features. The proband presented aged 12 months with hemophagocytic lymphohistiocytosis (HLH) closely followed by clinical varicella, both occurring within three weeks of measles, mumps, and rubella (MMR) and varicella vaccinations. There was a history of life-threatening influenza A virus (IAV) disease 2 months previously. Genetic investigation uncovered homozygosity for a novel nonsense variant in STAT2 (c. 1999C>T, p. Arg667Ter) that abrogated STAT2 protein expression. Compatible with STAT2 deficiency, dermal fibroblasts from the child demonstrated a defect of interferon-stimulated gene expression and a failure to mount an antiviral state in response to treatment with IFN-I, a phenotype that was rescued by lentiviral complementation by wild type STAT2. This case significantly expands the phenotypic spectrum of STAT2 deficiency. The occurrence of life-threatening influenza, which has not previously been reported in this condition, adds STAT2 to the list of monogenetic causes of this phenotype and underscores the critical importance of IFN-I and IFN-III to influenza immunity. The development of probable vaccine-strain varicella is also a novel occurrence in STAT2 deficiency, implying a role for IFN-I/III immunity in control of attenuated varicella zoster virus in vivo and reinforcing the susceptibility to pathologic effects of live-attenuated viral vaccines in disorders of IFN-I immunity. Finally, the occurrence of HLH in this case reinforces emerging links to hyperinflammation in patients with STAT2 deficiency and other related defects of IFN-I signaling-highlighting an important avenue for further scientific enquiry.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

A Novel Case of Homozygous Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency With Hemophagocytic Lymphohistiocytosis

Florian Gothe, Catherine F. Hatton, Linh Truong, Zofia Klimova, Veronika Kanderova, Martina Fejtkova, Angela Grainger, Venetia Bigley, Joanna Perthen, Dipayan Mitra, Ales Janda, Eva Fronkova, Dusana Moravcikova, Sophie Hambleton, Christopher J. A. Duncan

Summary: The case study presents a child with complete deficiency of the interferon alpha/beta receptor alpha chain (IFNAR1) who experienced fatal systemic hyperinflammation, possibly triggered by live-attenuated viral vaccination. This hyperinflammatory condition, meeting the criteria for hemophagocytic lymphohistiocytosis, is a new phenotype associated with inborn errors of type I interferon immunity.

CLINICAL INFECTIOUS DISEASES (2022)

Article Immunology

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

Adrian M. Shields, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, Malini Bhole, Evon Boules, Philip Bright, Charu Chopra, Lucy Cliffe, Betsy Cleave, John Dempster, Lisa Devlin, Fatima Dhalla, Lavanya Diwakar, Elizabeth Drewe, Christopher Duncan, Magdalena Dziadzio, Suzanne Elcombe, Shuayb Elkhalifa, Andrew Gennery, Harichandrana Ghanta, Sarah Goddard, Sofia Grigoriadou, Scott Hackett, Grant Hayman, Richard Herriot, Archana Herwadkar, Aarnoud Huissoon, Rashmi Jain, Stephen Jolles, Sarah Johnston, Sujoy Khan, James Laffan, Peter Lane, Lucy Leeman, David M. Lowe, Shanti Mahabir, Dylan James Mac Lochlainn, Elizabeth McDermott, Siraj Misbah, Fiona Moghaddas, Hadeil Morsi, Sai Murng, Sadia Noorani, Rachael O'Brien, Smita Patel, Arthur Price, Tasneem Rahman, Suranjith Seneviratne, Anna Shrimpton, Catherine Stroud, Moira Thomas, Katie Townsend, Prashantha Vaitla, Nisha Verma, Anthony Williams, Siobhan O. Burns, Sinisa Savic, Alex G. Richter

Summary: This study investigates the outcomes of 310 patients with primary or secondary immunodeficiency in the United Kingdom following SARS-CoV-2 infection, and finds significantly elevated mortality rates in both cohorts compared to the general population. Increasing age, pre-existing lymphopenia, and other co-morbidities are identified as additional risk factors for death from COVID-19 in this cohort.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

Article Allergy

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency

Florian Gothe, Jarmila Stremenova Spegarova, Catherine F. Hatton, Helen Griffin, Thomas Sargent, Sally A. Cowley, William James, Anna Roppelt, Anna Shcherbina, Fabian Hauck, Hugh T. Reyburn, Christopher J. A. Duncan, Sophie Hambleton

Summary: This study investigated the abnormality of IFN-I signaling in patients with STAT2 and IRF9 deficiency and found that it may contribute to inflammatory responses. IFN-alpha receptor signaling in cells lacking STAT2 or IRF9 was prolonged, and the transcriptional response resembled that of IFN-gamma.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Immunology

Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

Christopher J. A. Duncan, Morten K. Skouboe, Sophie Howarth, Anne K. Hollensen, Rui Chen, Malene L. Borresen, Benjamin J. Thompson, Jarmila Stremenova Spegarova, Catherine F. Hatton, Frederik F. Staeger, Mette K. Andersen, John Whittaker, Soren R. Paludan, Sofie E. Jorgensen, Martin K. Thomsen, Jacob G. Mikkelsen, Carsten Heilmann, Daniela Buhas, Nina F. Obro, Jakob T. Bay, Hanne Marquart, M. Teresa de la Morena, Joseph A. Klejka, Matthew Hirschfeld, Line Borgwardt, Isabel Forss, Tania Masmas, Anja Poulsen, Francisco Noya, Guy Rouleau, Torben Hansen, Sirui Zhou, Anders Albrechtsen, Reza Alizadehfar, Eric J. Allenspach, Sophie Hambleton, Trine H. Mogensen

Summary: This study investigated five children from Greenland, Canada, and Alaska who carried a homozygous IFNAR2 gene variant, resulting in increased vulnerability to viral infections. This finding highlights the essential role of Type I interferons in viral immunity and suggests the need for further population screening studies.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Article Geriatrics & Gerontology

Clinical frailty, and not features of acute infection, is associated with late mortality in COVID-19: a retrospective cohort study

Nikolaos Vlachogiannis, Kenneth F. Baker, Georgios Georgiopoulos, Charalampos Lazaridis, Ina Schim van der Loeff, Aidan T. Hanrath, Kateryna Sopova, Simon Tual-Chalot, Aikaterini Gatsiou, Ioakim Spyridopoulos, Kimon Stamatelopoulos, Christopher J. A. Duncan, Konstantinos Stellos

Summary: This study aims to identify predictors of early vs. late mortality in COVID-19 patients. The findings suggest that late mortality in COVID-19 patients is more strongly associated with premorbid clinical frailty than with severity of the acute infection phase.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2022)

Article Pediatrics

Case Report: Severe Acute Pulmonary COVID-19 in a Teenager Post Autologous Hematopoietic Stem Cell Transplant

Fabian J. S. van der Velden, Frederik van Delft, Stephen Owens, Judit Llevadias, Michael McKean, Lindsey Pulford, Yusri Taha, Grace Williamson, Quentin Campbell-Hewson, Sophie Hambleton, Rebecca Payne, Christopher Duncan, Catriona Johnston, Jarmila Spegarova, Marieke Emonts

Summary: In general, SARS-CoV-2 infection in children, including immunocompromised children, tends to be mild. However, a small percentage of pediatric patients may develop severe respiratory failure and require intensive care treatment.

FRONTIERS IN PEDIATRICS (2022)

Letter Urology & Nephrology

GSTM1 Copy Number and Kidney Disease in People With HIV

Rachel K. Y. Hung, Kerry-Lee Rosenberg, Victor David, Elizabeth Binns-Roemer, John W. Booth, Rachel Hilton, Julie Fox, Fiona Burns, Andrew Ustianowski, Catherine Cosgrove, Lisa Hamzah, James E. Burns, Amanda Clarke, David Chadwick, David A. Price, Stephen Kegg, Lucy Campbell, Kate Bramham, Caroline A. Sabin, Frank A. Post, Cheryl A. Winkler

KIDNEY INTERNATIONAL REPORTS (2022)

Article Hematology

Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

Marcela A. Ferrada, Sinisa Savic, Daniela Ospina Cardona, Jason C. Collins, Hugh Alessi, Fernanda Gutierrez-Rodrigues, Dinesh Babu Uthaya Kumar, Lorena Wilson, Wendy Goodspeed, James S. Topilow, Julie J. Paik, James A. Poulter, Tanaz A. Kermani, Matthew J. Koster, Kenneth J. Warrington, Catherine Cargo, Rachel S. Tattersall, Christopher J. A. Duncan, Anna Cantor, Patrycja Hoffmann, Elspeth M. Payne, Hanna Bonnekoh, Karoline Krause, Edward W. Cowen, Katherine R. Calvo, Bhavisha A. Patel, Amanda K. Ombrello, Daniel L. Kastner, Neal S. Young, Achim Werner, Peter C. Grayson, David B. Beck

Summary: Somatic mutations in UBA1 cause VEXAS syndrome, an adult-onset inflammatory disease with high mortality and clinical heterogeneity. Ear chondritis is associated with increased survival, while transfusion dependence and specific gene variants are associated with decreased survival. The study demonstrates the impact of gene mutations on translation and survival rate.
Article Cell & Tissue Engineering

Conjunctival epithelial cells resist productive SARS-CoV-2 infection

Robert M. Jackson, Catherine F. Hatton, Jarmila Stremenova Spegarova, Maria Georgiou, Joseph Collin, Emily Stephenson, Bernard Verdon, Iram J. Haq, Rafiqul Hussain, Jonathan M. Coxhead, Hardeep-Singh Mudhar, Bart Wagner, Megan Hasoon, Tracey Davey, Paul Rooney, C. M. Anjam Khan, Chris Ward, Malcolm Brodlie, Muzlifah Haniffa, Sophie Hambleton, Lyle Armstrong, Francisco Figueiredo, Rachel Queen, Christopher J. A. Duncan, Majlinda Lako

Summary: Conjunctival epithelial cells, the largest exposed epithelium of the ocular surface tissue, may serve as a potential route for SARS-CoV-2 entry. Through the use of an organotypic model and molecular assays, it was found that although conjunctival cells are susceptible to SARS-CoV-2 infection, productive infection does not occur. Furthermore, the early innate immune response in conjunctival cells is characterized by robust NF-KB activity without activation of antiviral interferon signaling.

STEM CELL REPORTS (2022)

Article Microbiology

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Brian J. Willett, Joe Grove, Oscar A. MacLean, Craig Wilkie, Giuditta De Lorenzo, Wilhelm Furnon, Diego Cantoni, Sam Scott, Nicola Logan, Shirin Ashraf, Maria Manali, Agnieszka Szemiel, Vanessa Cowton, Elen Vink, William T. Harvey, Chris Davis, Patawee Asamaphan, Katherine Smollett, Lily Tong, Richard Orton, Joseph Hughes, Poppy Holland, Vanessa Silva, David J. Pascall, Kathryn Puxty, Ana da Silva Filipe, Gonzalo Yebra, Sharif Shaaban, Matthew T. G. Holden, Rute Maria Pinto, Rory Gunson, Kate Templeton, Pablo R. Murcia, Arvind H. Patel, Paul Klenerman, Susanna Dunachie, John Haughney, David L. Robertson, Massimo Palmarini, Surajit Ray, Emma C. Thomson

Summary: Vaccines based on the spike protein of SARS-CoV-2 are vital in combating COVID-19, but the emergence of the Omicron variant poses a threat to this strategy. Studies have shown that the Omicron variant evades neutralization by sera from individuals vaccinated with different vaccines and reduces real-world vaccine effectiveness, although booster vaccination can partially restore its effectiveness. Additionally, the Omicron variant exhibits distinct cell entry pathways and phenotypes, which may contribute to its rapid global spread and altered pathogenicity.

NATURE MICROBIOLOGY (2022)

Article Biochemistry & Molecular Biology

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Alexander J. Mentzer, Daniel O'Connor, Sagida Bibi, Irina L. Chelysheva, Elizabeth A. Clutterbuck, Tesfaye Demissie, Tanya Dinesh, Nick M. Edwards, Sally Felle, Shuo C. Feng, Amy Flaxman, Eleanor Karp-Tatham, Grace Li, Xinxue J. Liu, Natalie Marchevsky, Leila Godfrey, Rebecca K. Makinson, Maireid O. Bull, Jamie N. Fowler, Bana Alamad, Tomas Malinauskas, Amanda Chong, Katherine Sanders, Robert Shaw, Merryn Voysey, Matthew D. Snape, Andrew J. Pollard, Teresa Lambe, Julian C. Knight

Summary: Variation in antibody levels elicited by the COVID-19 vaccine ChAdOx1 nCov-19 is linked to specific major histocompatibility complex class II alleles, providing insight into the breadth of immune response among vaccinated individuals. HLA-DQB1*06 allele is associated with higher levels of anti-RBD antibody and decreased risk of breakthrough infection. These findings have implications for future vaccine design and implementation.

NATURE MEDICINE (2023)

Article Medicine, General & Internal

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Peter W. Horby, Jonathan R. Emberson, Marion Mafham, Mark Campbell, Leon Peto, Guilhenne Pessoa-Amorim, Enti Spata, Natalie Staplin, Catherine Lowe, David R. Chadwick, Christopher Brightling, Richard Stewart, Paul Collini, Abdul Ashish, Christopher A. Green, Ben Prudon, Timothy Felton, Anthony Kerry, J. Kenneth Baillie, Maya H. Such, Jeremy Day, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard Haynes, Martin J. Landray

Summary: This study evaluated the use of baricitinib in the treatment of patients hospitalized with COVID-19. The results showed that baricitinib significantly reduced the risk of death, although the effect size was slightly smaller than previous trials. Overall evidence suggests that JAK inhibitors can reduce mortality in hospitalized COVID-19 patients by about 20%.

LANCET (2022)

Article Respiratory System

The trajectory of COVID-19 cardiopulmonary disease: insights from an autopsy study of community-based, pre-hospital deaths

Luke Milross, Joaquim Majo, Julian Pulle, Sam Hoggard, Nigel Cooper, Bethany Hunter, Christopher J. A. Duncan, Andrew Filby, Andrew J. Fisher

Summary: This study investigated patterns of lung and heart injury in community-based COVID-19-attributable deaths. The results showed various lung injury patterns and identified factors that may have contributed to the lack of hospitalization, including low symptom burden, rapidly progressive disease, and psychosocial factors.

ERJ OPEN RESEARCH (2022)

Article Medicine, General & Internal

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R. Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A. Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J. Kenneth Baillie, Maya H. Bitch, Lucy C. Chappell, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, David M. Weinreich, Richard Haynes, Martin J. Landray

Summary: This study evaluated the efficacy and safety of the combination therapy of casirivimab and imdevimab in patients hospitalized with COVID-19. The results showed that this combination therapy reduced the 28-day mortality rate in patients without detectable antibodies to SARS-CoV-2 infection at baseline, but not in those with detectable antibodies.

LANCET (2022)

暂无数据